Due to well-known complications of metal-on-metal hip resurfacing arthroplasty the indication for this procedure has significantly decreased over the past years. As a high number of patients is currently living with resurfacing implants, however, there is a clear need for information about the longterm results and especially about the rate of local as well as systemic adverse effects.

We retrospectively reviewed our first 95 patients who had 100 consecutive BHR hip resurfacings performed from 1998–2001. Median age at surgery was 52 years (range, 28–69 years); 49% were men. After a mean follow-up period of 16.1 years (range 15.2 – 17.6 years) we assessed survival rate (revision for any reason as endpoint), radiographic changes and patient-related outcome in patients who had not undergone revision. In addition we measured whole blood concentrations of cobalt at follow-up.

17% of our patients in the original cohort were lost to follow-up. In the remaining patients the 16-year survivorship was 80.1%. The overall survival rate was slightly higher in males (80.6%) than in females (77.1%). The WOMAC overall score showed a median value of 91.7 points (range 35.4 – 100). Median whole blood ion levels were 1.9 µg/L for cobalt (0.6 – 140.2 µg/L), 14.9% of patients showed elevated levels. The number of patients with relevant radiographic signs of local adverse reactions to metal debris was relatively low.

In contrast to earlier reports and very few other longterm studies our results show an unsatisfactory performance of resurfacing. In particular the outcome of male patients deteriorated between 10 and 16 years of follow-up. Although only a small number of patients shows relevant elevation of metal-ion levels, the clinical relevance has still to be determined.